
CLPT Stock Forecast & Price Target
CLPT Analyst Ratings
Bulls say
ClearPoint Neuro Inc is experiencing promising financial momentum, highlighted by a reported 17% topline growth in 2023 and a significant reduction in cash burn. The company is poised for further success in 2024, with expectations of at least 20% revenue growth driven by the expansion of its partnership base and enhanced service offerings in the Biologics sector. Additionally, the recent product approvals, record system installations, and supportive clinical publications indicate a robust foundation for sustained growth and improved profitability moving forward.
Bears say
ClearPoint Neuro Inc has demonstrated a significant decrease in cash burn, reducing it from $5.8 million in the first quarter of 2023 to $1.2 million by the fourth quarter of 2023. While the company anticipates continuing this trend into 2024, the persistently high cash burn prior to this reduction raises concerns about the overall financial stability and the efficiency of their operations. Additionally, a continued reliance on variable revenue streams inherent in medical device sales may pose challenges to sustained profitability and long-term growth potential.
This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.
CLPT Analyst Forecast & Price Prediction
Start investing in CLPT
Order type
Buy in
Order amount
Est. shares
0 shares